

Emanuela Scarpi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1067592/emanuela-scarpi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245
papers

6,437
citations

45
h-index

70
g-index

288
ext. papers

7,353
ext. citations

4.3
avg, IF

5.15
L-index

#	Paper	IF	Citations
245	A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , 1999 , 17, 231-9	4.8	323
244	Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , 1999 , 17, 240-7	4.8	303
243	Palliative sedation in end-of-life care and survival: a systematic review. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1378-83	2.2	216
242	Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. <i>Cancer</i> , 1995 , 75, 2613-22	6.4	170
241	Palliative sedation therapy does not hasten death: results from a prospective multicenter study. <i>Annals of Oncology</i> , 2009 , 20, 1163-9	10.3	137
240	Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 881-8	8.8	100
239	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 33210-9	3.3	98
238	Prospective comparison of prognostic scores in palliative care cancer populations. <i>Oncologist</i> , 2012 , 17, 446-54	5.7	96
237	Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. <i>Journal of Palliative Medicine</i> , 2008 , 11, 492-501	2.2	94
236	Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , 1997 , 13, 1-9	4.8	93
235	High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. <i>Annals of Oncology</i> , 2001 , 12, 289-300	10.3	93
234	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016 , 7, 376	5.6	93
233	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016 , 7, 54564-54571	3.3	89
232	Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. <i>European Journal of Cancer</i> , 2016 , 65, 61-8	7.5	87
231	177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1845-51	8.8	86
230	A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. <i>Supportive Care in Cancer</i> , 2005 , 13, 888-94	3.9	86
229	Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. <i>European Journal of Cancer</i> , 2016 , 69, 110-118	7.5	80

228	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. <i>Scientific Reports</i> , 2018 , 8, 4254	4.9	78
227	Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. <i>Heart</i> , 2013 , 99, 634-9	5.1	78
226	Erratum to Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 1-1		78
225	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , 2016 , 7, 67142-67149	3.3	76
224	Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. <i>Oncologist</i> , 2011 , 16, 1793-9	5.7	74
223	Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. <i>Supportive Care in Cancer</i> , 1997 , 5, 130-5	3.9	74
222	Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with Lu-D OTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 490-499	8.8	72
221	Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 264-9	3	67
220	Transbronchial biopsy is useful in predicting UIP pattern. <i>Respiratory Research</i> , 2012 , 13, 96	7.3	67
219	Impact of palliative care unit admission on symptom control evaluated by the edmonton symptom assessment system. <i>Journal of Pain and Symptom Management</i> , 2005 , 30, 367-73	4.8	67
218	High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1377-84	3.1	66
217	Lymph node micrometastases in early gastric cancer and their impact on prognosis. <i>World Journal of Surgery</i> , 2003 , 27, 558-61	3.3	66
216	(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1276-83	8.8	64
215	Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 10332-42	6.3	64
214	A multicenter case-control study in Italy on hematolymphopietic neoplasms and occupation. <i>Epidemiology</i> , 2001 , 12, 78-87	3.1	64
213	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. <i>Clinical Lung Cancer</i> , 2016 , 17, 384-390	4.9	60
212	Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016 , 7, 37839-37845	3.3	60
211	Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1040-6	8.8	60

210	Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1744-50	2.8	55
209	Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3125-34	2.2	52
208	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2719-25	4	51
207	Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices. <i>Occupational and Environmental Medicine</i> , 1996 , 53, 652-7	2.1	50
206	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 75, 368-373	10.2	50
205	Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. <i>Journal of Translational Medicine</i> , 2013 , 11, 135	8.5	48
204	Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. <i>Oncology</i> , 2013 , 84, 150-7	3.6	48
203	Multiple marker detection in peripheral blood for NSCLC diagnosis. <i>PLoS ONE</i> , 2013 , 8, e57401	3.7	48
202	Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2000 , 63, 181-92	4.4	47
201	Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. <i>World Journal of Surgery</i> , 2008 , 32, 2661-7	3.3	46
200	Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. <i>Clinical Breast Cancer</i> , 2011 , 11, 369-75	3	45
199	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	44
198	Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. <i>Breast Cancer Research and Treatment</i> , 1998 , 49, 209-17	4.4	44
197	Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on job titles. <i>Occupational and Environmental Medicine</i> , 1995 , 52, 374-9	2.1	44
196	KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). <i>PLoS ONE</i> , 2014 , 9, e92071	3.7	43
195	Role of biological markers in the clinical outcome of colon cancer. <i>British Journal of Cancer</i> , 2002 , 87, 868-75	8.7	41
194	HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2708-12	2.2	41
193	Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?. <i>Leukemia and Lymphoma</i> , 2000 , 39, 301-10	1.9	41

192	Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. <i>Lung Cancer</i> , 1999 , 24, 81-8	5.9	40
191	Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. <i>Gastric Cancer</i> , 2013 , 16, 549-54	7.6	39
190	Ipilimumab in advanced melanoma: reports of long-lasting responses. <i>Melanoma Research</i> , 2012 , 22, 263-70	3.3	39
189	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016 , 11, e0158952	3.7	39
188	Investigation of receptor radionuclide therapy with Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 923-930	8.8	38
187	The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2008 , 16, 359-70	3.9	38
186	Multiple myeloma and work in agriculture: results of a case-control study in Forlì Italy. <i>Cancer Causes and Control</i> , 1998 , 9, 277-83	2.8	37
185	Lymph node micrometastases in patients with early gastric cancer: experience with 139 patients. <i>Annals of Surgical Oncology</i> , 2001 , 8, 170-4	3.1	36
184	Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. <i>International Journal of Cancer</i> , 2002 , 98, 228-33	7.5	35
183	Tumor microvessel density and prognosis in node-negative breast cancer. <i>International Journal of Cancer</i> , 2000 , 89, 74-80	7.5	35
182	Transdermal Fentanyl as A Front-Line Approach to Moderate-Severe Pain: A meta-analysis of Randomized Clinical Trials. <i>Journal of Palliative Care</i> , 2009 , 25, 172-180	1.8	33
181	A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. <i>Bone Marrow Transplantation</i> , 2006 , 38, 407-12	4.4	33
180	Managing chronic pain: results from an open-label study using MC5-A Calmare [®] device. <i>Supportive Care in Cancer</i> , 2012 , 20, 405-12	3.9	31
179	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	31
178	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. <i>Journal of Translational Medicine</i> , 2012 , 10, 87	8.5	31
177	Prognostic relevance of histological grade and its components in node-negative breast cancer patients. <i>Modern Pathology</i> , 2004 , 17, 1038-44	9.8	31
176	Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. <i>Clinical Lung Cancer</i> , 2015 , 16, e223-8	4.9	30
175	Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. <i>Chest</i> , 2009 , 135, 1596-1609	5.3	30

174	Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. <i>Melanoma Research</i> , 2011 , 21, 524-9	3.3	30
173	Circulating tumor cells in early breast cancer: A connection with vascular invasion. <i>Cancer Letters</i> , 2015 , 367, 43-8	9.9	29
172	Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care. <i>Supportive Care in Cancer</i> , 2012 , 20, 2829-36	3.9	27
171	FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy. <i>Journal of Cancer</i> , 2012 , 3, 241-5	4.5	27
170	Nuclear NHERF1 expression as a prognostic marker in breast cancer. <i>Cell Death and Disease</i> , 2013 , 4, e904	9.8	26
169	eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , 2016 , 7, 27988-99	3.3	26
168	Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015 , 10, e0134732	3.7	25
167	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , 2016 , 7, 15243-51	3.3	25
166	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019 , 116, 158-168	7.5	23
165	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018 , 13, 469-479	5	23
164	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <i>Journal of Translational Medicine</i> , 2015 , 13, 258	8.5	23
163	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 156-63	3.6	21
162	Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2647-54	4	21
161	Palliative sedation in end-of-life care. <i>Current Opinion in Oncology</i> , 2013 , 25, 360-7	4.2	20
160	RANKL: A promising circulating marker for bone metastasis response. <i>Oncology Letters</i> , 2016 , 12, 2970-2975	2.5	20
159	Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. <i>OncoTargets and Therapy</i> , 2018 , 11, 6555-6567	4.4	20
158	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. <i>Translational Oncology</i> , 2019 , 12, 585-595	4.9	19
157	Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 122-7	3.8	19

156	Evaluation of the cost of home care for terminally ill cancer patients. <i>Supportive Care in Cancer</i> , 1997 , 5, 396-401	3.9	19
155	Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. <i>Cancer</i> , 1997 , 79, 226-32	6.4	19
154	Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. <i>Oncotarget</i> , 2017 , 8, 13142-13156	3.3	18
153	Benefit from anthracyclines in relation to biological profiles in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 307-18	4.4	18
152	CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 15767-77	6.3	18
151	Palliative sedation for intolerable suffering. <i>Current Opinion in Oncology</i> , 2014 , 26, 389-94	4.2	18
150	Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 182-9	3.3	18
149	Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. <i>Thorax</i> , 2008 , 63, 843-4	7.3	18
148	Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. <i>Oncotarget</i> , 2017 , 8, 2423-2436	3.3	18
147	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. <i>Scientific Reports</i> , 2017 , 7, 1293	4.9	17
146	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919866065	5.4	17
145	Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. <i>Journal of Translational Medicine</i> , 2014 , 12, 262	8.5	17
144	Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1862-7	4	17
143	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 775-84	4.4	17
142	Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. <i>Clinical and Developmental Immunology</i> , 2010 , 2010, 504979		17
141	The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. <i>Oncology</i> , 2011 , 80, 225-31	3.6	17
140	Role of SIRT-3, p-mTOR and HIF-1 α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
139	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , 2019 , 27, 2425-2434	3.9	16

138	The role of growth patterns, according to Kodama's classification, and lymph node status, as important prognostic factors in early gastric cancer: analysis of 412 cases. <i>Gastric Cancer</i> , 2000 , 3, 134-140	7.6	15
137	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 79-86	4.4	15
136	Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 348-354	8.8	15
135	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 44-53	7	15
134	Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?. <i>BMC Cancer</i> , 2018 , 18, 348	4.8	14
133	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , 2019 , 79, 1211-1220	4.2	14
132	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. <i>Oncotarget</i> , 2016 , 7, 10193-202	3.3	14
131	Identification of occult micrometastases in patients with early gastric cancer using anti-cytokeratin monoclonal antibodies. <i>Oncology Reports</i> , 2000 , 7, 535-9	3.5	14
130	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018 , 8, 15442	4.9	14
129	Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1874-81	7.5	13
128	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 240.e1-240.e11	2.8	13
127	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 96	12.8	13
126	Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study. <i>Journal of Chemotherapy</i> , 2011 , 23, 300-5	2.3	13
125	Comparison between different cell kinetic variables in human breast cancer. <i>Cell Proliferation</i> , 2000 , 33, 75-89	7.9	13
124	Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2017 , 28, 1910-1916	10.3	12
123	Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. <i>European Radiology</i> , 2018 , 28, 2969-2978	8	12
122	Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 65	12.8	12
121	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. <i>Tumori</i> , 2012 , 98, 696-701	1.7	12

120	RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 10683-93	6.3	12
119	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020 , 123, 982-987	8.7	12
118	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018 , 104, 476-479	1.7	12
117	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1140-7	4.6	11
116	Improved stool DNA integrity method for early colorectal cancer diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2553-60	4	11
115	MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 24097-112	6.3	11
114	Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. <i>Journal of Translational Medicine</i> , 2011 , 9, 94	8.5	11
113	NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 65730-65742	3.3	11
112	Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. <i>Cellular Oncology</i> , 2009 , 31, 11-7		11
111	Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0167906	3.7	11
110	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?. <i>Translational Oncology</i> , 2018 , 11, 950-956	4.9	11
109	Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. <i>Cancer Management and Research</i> , 2019 , 11, 1377-1383	3.6	10
108	Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?. <i>Frontiers in Endocrinology</i> , 2018 , 9, 137	5.7	10
107	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017 , 7, 15541	4.9	10
106	Vitamin D status among long-term survivors of testicular cancer. <i>Oncotarget</i> , 2017 , 8, 36780-36786	3.3	10
105	Bone metastases detection by circulating biomarkers: OPG and RANK-L. <i>International Journal of Oncology</i> , 2011 , 39, 255-61	4.4	9
104	Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. <i>Technology in Cancer Research and Treatment</i> , 2012 , 11, 163-7	2.7	9
103	Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 259-64	4.4	9

102	Gastric cancer mortality in the spouses of patients who died from gastric cancer. <i>International Journal of Epidemiology</i> , 2002 , 31, 468-472	7.8	9
101	Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. <i>Tumori</i> , 2011 , 97, 367-73	1.7	9
100	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 255-63	4.5	9
99	Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. <i>International Journal of Cancer</i> , 2016 , 138, 110-20	7.5	9
98	Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience. <i>Technology in Cancer Research and Treatment</i> , 2015 , 14, 721-7	2.7	8
97	Early Gastric Cancer: Clinical Behavior and Treatment Options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG). <i>Oncologist</i> , 2018 , 23, 852-858	5.7	8
96	High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2017 , 21, 766-773	1.3	8
95	New biomarkers to predict the evolution of in situ breast cancers. <i>BioMed Research International</i> , 2014 , 2014, 159765	3	8
94	Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. <i>Oncologist</i> , 2014 , 19, 1276-83	5.7	8
93	Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 152-160	8.8	8
92	Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. <i>Cancers</i> , 2019 , 11,	6.6	7
91	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 426-431	3.3	7
90	Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. <i>Radiation Oncology</i> , 2019 , 14, 112	4.2	7
89	GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. <i>Hepato-Gastroenterology</i> , 2011 , 58, 599-603		7
88	Independent Negative Prognostic Role of TCF1 Expression within the Wnt/ECatenin Signaling Pathway in Primary Breast Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	6
87	Controversial issues in thromboprophylaxis with low-molecular weight heparins in palliative care. <i>Journal of Pain and Symptom Management</i> , 2008 , 36, e3-4	4.8	6
86	Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 343-9	4.4	6
85	Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2001 , 68, 101-10	4.4	6

84	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. <i>Translational Oncology</i> , 2020 , 13, 186-192	4.9	6
83	Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 1325	5.3	6
82	Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients. <i>Diagnostics</i> , 2021 , 11,	3.8	6
81	IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. <i>Cancer Management and Research</i> , 2018 , 10, 5659-5666	3.6	6
80	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. <i>BMC Cancer</i> , 2018 , 18, 1267	4.8	6
79	Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 705331	5.3	6
78	Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. <i>Scientific Reports</i> , 2017 , 7, 10426	4.9	5
77	Reply to E. Schildmann et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4177-4178	2.2	5
76	Gastric cancer mortality in the spouses of patients who died from gastric cancer. <i>International Journal of Epidemiology</i> , 2002 , 31, 468-472	7.8	5
75	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. <i>Tumori</i> , 2012 , 98, 696-701	1.7	5
74	Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920958363	5.4	5
73	No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). <i>Scientific Reports</i> , 2016 , 6, 37621.9	4.9	5
72	Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>OncoTargets and Therapy</i> , 2018 , 11, 5261-5268	4.4	5
71	Impact of admission to hospice on pain intensity and type of pain therapies administered. <i>Supportive Care in Cancer</i> , 2016 , 24, 225-232	3.9	4
70	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017 , 77, 1012-1019	4.2	4
69	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-13	3.6	4
68	An aggressive early gastric cancer: Kodama's PenA type. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1186-1190	3.6	4
67	Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 593-9	2.7	4

66	Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions. <i>Oncotarget</i> , 2016 , 7, 40719-40724	3.3	4
65	Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients 1997 , 5, 130		4
64	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020 , 10, 18190	4.9	4
63	Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019 , 43, e76-e78	2.4	4
62	Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 716467	5.3	4
61	Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?. <i>Journal of Oncology</i> , 2019 , 2019, 1393505	4.5	3
60	methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. <i>Oncology Letters</i> , 2015 , 9, 1432-1438	2.6	3
59	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a analysis of the IBIS 3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919888999	5.4	3
58	Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1031-1031	2.2	3
57	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3020-3020	2.2	3
56	Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicines</i> , 2020 , 8,	4.8	3
55	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021 , 35, 2813-2826	10.7	3
54	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
53	Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN. <i>Analytical Cellular Pathology</i> , 2012 , 35, 377-380	3.4	2
52	The limit of therapies in oncology. <i>Journal of Medicine and the Person</i> , 2010 , 8, 112-120		2
51	Safety and efficacy of Scrambler therapy for cancer pain.. <i>Journal of Clinical Oncology</i> , 2010 , 28, e19591-e19591		2
50	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16059-e16059	2.2	2
49	HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 601-601	2.2	2

48	Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920937427	5.4	2
47	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021 , 152, 49-59	7.5	2
46	Tumor microvessel density and prognosis in node-negative breast cancer 2000 , 89, 74		2
45	Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1777-1778	8.8	1
44	Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	1
43	¹¹¹ In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance. <i>Nuclear Medicine Communications</i> , 2015 , 36, 135-42	1.6	1
42	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
41	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. <i>OncoTargets and Therapy</i> , 2017 , 10, 4657-4664	4.4	1
40	Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone). <i>Annals of Surgical Oncology</i> , 2013 , 20, 2958-63	3.1	1
39	Biology matters: the clinical impact of single-receptor discordance on breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 851	10.3	1
38	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7600-7600	2.2	1
37	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 617-617	2.2	1
36	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11532-11532	2.2	1
35	Prognostic and predictive role of circulating eNOS and EPHB4 in metastatic colorectal cancer patients receiving bevacizumab.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23083-e23083	2.2	1
34	Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1042-1042	2.2	1
33	Efficacy of bevacizumab in second-line versus first-line treatment of metastatic colorectal cancer: Results from a new methodological approach based on the ITACa strategy trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3546-3546	2.2	1
32	Lymph Node Micrometastases in Patients With Early Gastric Cancer: Experience With 139 Patients 2001 , 8, 170		1
31	Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	1

30	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 547-547	2.2	1
29	Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis. <i>Gastric Cancer</i> , 2021 , 24, 392-401	7.6	1
28	Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-7. <i>European Urology</i> , 2018 , 73, e9-e10	10.2	1
27	Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. <i>Biomolecules</i> , 2021 , 11,	5.9	1
26	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.. <i>BMC Medicine</i> , 2022 , 20, 48	11.4	0
25	Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 732900	5.6	0
24	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2021 , 16, 538	7.9	0
23	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 203-203	2.2	0
22	Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5039-5039	2.2	0
21	The challenge of prognostication in palliative radiotherapy: the way forward is shared decision-making. <i>Supportive Care in Cancer</i> , 2020 , 28, 1545-1546	3.9	0
20	Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920977139	5.4	0
19	Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab.. <i>Scientific Reports</i> , 2022 , 12, 3385	4.9	0
18	Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients. <i>Cancers</i> , 2022 , 14, 2510	6.6	0
17	PP 39 Multi-determinants analysis of molecular alterations as predictor of resistance to cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2011 , 47, S32-S33	7.5	
16	Reproducibility of results on chronic pain with MC5-A Calmare [®] device from independent studies. <i>Supportive Care in Cancer</i> , 2011 , 19, 1685-6	3.9	
15	Studies signaling the prognostic factors of terminally ill phases. <i>Journal of Pain and Symptom Management</i> , 1996 , 12, 205	4.8	
14	Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS396-TPS396	2.2	
13	The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 545-545	2.2	

- 12 High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer.. *Journal of Clinical Oncology*, **2014**, 32, 4540-4540 2.2
- 11 RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.. *Journal of Clinical Oncology*, **2014**, 32, 11128-11128 2.2
- 10 18F-fluorocholine positron emission tomography/computed tomography for early outcome prediction in metastatic castration-resistant prostate cancer patients treated with enzalutamide: A proof-of-principle study.. *Journal of Clinical Oncology*, **2014**, 32, e16040-e16040 2.2
- 9 Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, 448-448 2.2
- 8 Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. *Journal of Clinical Oncology*, **2015**, 33, e15156-e15156 2.2
- 7 Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. *Journal of Clinical Oncology*, **2015**, 33, e15595-e15595 2.2
- 6 eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. *Journal of Clinical Oncology*, **2015**, 33, e15157-e15157 2.2
- 5 Is Vit D serum concentration related to Italian and Tanzanian breast cancer cases?. *Journal of Clinical Oncology*, **2015**, 33, e22248-e22248 2.2
- 4 Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 231-231 2.2
- 3 Circulating AR copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.. *Journal of Clinical Oncology*, **2016**, 34, e16583-e16583 2.2
- 2 Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience.. *Journal of Clinical Oncology*, **2016**, 34, 5558-5558 2.2
- 1 Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. *Journal of Clinical Oncology*, **2017**, 35, e20676-e20676 2.2